We observed 5 patients with subcutaneous panniculitis-
like T-cell lymphoma (SPTCL) who were unusual, in that they also exhibited features of lupus erythematosus (LE). This observation is in keeping with a recent study that reported an increased rate of autoimmune disease, including systemic lupus erythematosus (SLE), among patients with SPTCL. In all cases, attributes indicating SPTCL included an infiltrate of lymphocytes with pleomorphic nuclei involving subcutaneous lobules exhibiting a cytotoxic T-cell (CD3 + /CD8 + /bF1 + ) immunophenotype. Additionally, a high proliferation rate and a monoclonal T-cell receptor-g gene rearrangement were observed in most cases. The manifestations of LE in these patients included a spectrum of clinical and histopathological abnormalities. Clinical manifestations of LE included, in some patients, morphologic evidence of lupus erythematosus panniculitis (LEP) with subcutaneous nodules that healed with lipoatrophy on the face. In addition, all the patients exhibited serologic and/or extracutaneous end-organ abnormalities seen in patients with SLE, with 2 patients having sufficient findings to meet American College of Rheumatology criteria for SLE. Histopathological evidence of LE included vacuolar change at the dermal-epidermal interface in 3 patients, 2 of whom also showed interstitial deposition of mucin in the reticular dermis. One of these patients also had findings of LEP in the subcutaneous lobules with clusters of CD20 + B cells partially arranged within germinal centers. In 2 patients in which neither the epidermis nor dermis was available for review, histopathological features of LE included, in one patient, a few small clusters of CD123 + plasmacytoid dendritic cells within the adipose tissue and, in the other patient, a positive direct immunofluorescence test (lupus band) on clinically uninvolved and lesional skin. Our study shows that some patients show overlap between SPTCL and LE. We suspect that these patients may suffer from both diseases concomitantly. Furthermore, patients with LE, particularly LEP, should be monitored for evolution into SPTCL with biopsy of any subcutaneous lesion that is not typical of LEP. Additionally, screening for cutaneous LE and SLE could be considered in patients with SPTCL.
INTRODUCTION
A recent large European Organization for Research and Treatment of Cancer study of 63 patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL) indicated that 19% had an associated autoimmune disease, including 4 with systemic lupus erythematosus (SLE). 1 We encountered 5 patients in routine practice or in consultation who exhibited typical features of SPTCL but were unusual, in that they also had manifestations of lupus erythematosus (LE). The features of LE included a spectrum of findings from typical clinical cutaneous lesions, to serologic and extracutaneous end-organ abnormalities typical of SLE, to findings of LE seen on histopathological sections from skin biopsies.
Reports addressing a relationship between SPTCL and LE have focused primarily on delineating histopathological and clinical features that distinguish SPTCL from lupus erythematosus panniculitis (LEP). [2] [3] [4] [5] Indeed, it can be very challenging to differentiate between SPTCL and LEP on histopathological grounds. 6, 7 Microscopically, LEP is typically characterized by a lymphocytic infiltrate within subcutaneous lobules with little septal involvement, fat necrosis, and the presence of histiocytes containing karyorrhectic debrisalthough these features can also be seen in SPTCL. Microscopic findings that can help to distinguish LEP from SPTCL include features typical of cutaneous LE in the epidermis and dermis, including vacuolar change at the dermal-epidermal interface, periadnexal lymphocytic infiltrates, and interstitial deposition of mucin in the reticular dermis. The presence in the subcutis of lymphoid follicles with reactive germinal centers, clusters of B lymphocytes, and a mixed infiltrate with prominent plasma cells also favors LEP. 4 A recently elucidated clue to LEP is presence of clusters of CD123 + plasmacytoid dendritic cells (pDCs) within the subcutaneous lobules and, if present, within the dermal infiltrates, similar to that which can be seen in chronic discoid LE. 8 In addition, a series of moderate size has shown that the T-cell population in LEP is polyclonal. 4 However, in the absence of these additional findings of LE, it can be very difficult to distinguish histopathologically between these 2 entities.
The clinical presentations can also be similar. LEP is one of the few panniculitides that commonly causes lesions above the waist, and lesions of SPTCL can also be above the waist. Both can form plaques, and ulceration can complicate both conditions. However, the lesions of LEP are more apt to occur on the face and to resolve with atrophy, forming gullies. 9 By contrast, lesions of SPTCL typically are found on the trunk and extremities and rarely on the face. 1 In this report, we aim to characterize in detail the patients we encountered who had SPTCL but who also exhibited manifestations of LE.
PATIENTS AND METHODS

Patients
Data from 5 patients with the diagnosis of SPTCL and simultaneous signs of LE were retrieved from the dermatopathology files at the Medical University of Graz, Graz, Austria. Four of these 5 cases had been sent in consultation. When available, clinical and follow-up data were obtained from the referring physicians. In all cases, the diagnosis of SPTCL was made in accordance with the criteria listed in the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas. 10 Although the American College of Rheumatology (ACR) classification criteria for SLE were developed to provide homogeneity in clinical research studies rather than for clinical diagnosis, patients who meet 4 of the 11 criteria are standardly admitted into research studies on lupus. 11, 12 Therefore, we regarded patients as having SLE if they met 4 of the 11 ACR classification criteria.
Immunohistology
Detailed immunophenotypic analysis was performed on routinely fixed paraffin-embedded tissue sections according to a previously described 3-step immunoperoxidase technique using a broad panel of monoclonal antibodies (bF1: Endogen; CD3, CD8, CD20, CD30, and MIB-1: Dako; CD4, CD5, and CD56: Novocastra; TIA-1: Coulter; granzyme B: Monosan; and CD123: BD Biosciences). 13 
Molecular Biology
Polymerase chain reaction analysis of the T-cell receptor (TCR)-g gene (seeking clonal rearrangement) was performed on routinely fixed paraffin-embedded tissue specimens according to standard procedures as described previously [14] [15] [16] with minor modifications. 17 
In Situ Hybridization for Epstein-Barr Virus
Epstein-Barr virus (EBV) in situ hybridization was performed on routinely fixed paraffin-embedded tissue specimens according to standard procedures 18 using the EBER-1 in situ hybridization kit by Kreatech Diagnostic (Amsterdam, The Netherlands).
RESULTS
Clinical and histopathological features of patients are summarized in Table 1 .
Case 1
A 52-year-old woman had a 15-year history of lesions on her face and extremities characterized by ''panniculitis'' with evolution into lipoatrophy. She had a known diagnosis of SLE, with interstitial nephropathy with proteinuria (quantity unknown), anemia, 3 positive antinuclear antibody (ANA) tests (titers unknown), a positive anti-double-stranded DNA (anti-dsDNA) antibody test at a titer of 1:80, 2 positive anti-Ro antibody tests, and a direct immunofluorescence (DIF) test performed on biopsies from clinically uninvolved and lesional skin that revealed a granular deposition of immunoglobulin (Ig) M and IgG at the dermal-epidermal junction. Currently, the SLE is well controlled with hydroxychloroquine and oral corticosteroids, and there are no signs of recurrence or progression of the SPTCL.
Case 2
A 22-year-old male presented with a several month history of swelling on the left face associated with fevers, lymphadenopathy, anemia, and neutropenia. He had experienced a similar episode many years before with swelling on the right face, which eventuated in significant lipoatrophy. The ANA was negative. His disease had been successfully controlled with hydroxychloroquine, and he had not developed new panniculitic lesions 19 months after first diagnosis.
Case 3
A 22-year-old woman presented with infiltrated (panniculitis like) lesions on the face and extremities with evolution into lipoatrophy ( Fig. 1 ). She had a known diagnosis of SLE with a positive ANA at a titer of 1:2560, a positive anti-dsDNA antibody, renal failure requiring dialysis, a Coombspositive hemolytic anemia, and episodes of fever. She died of hemophagocytic syndrome with active lesions of SPTCL 41 months after her initial diagnosis of SPTCL. This patient was included in a prior series. 1
Case 4
A 20-year-old woman presented with subcutaneous lesions on the extremities. Antibodies to dsDNA were positive (titer unknown), although by report, the ANA was negative. Unfortunately, additional clinical information and follow-up data were not available.
Case 5
A 20-year-old female had a 5-year history of subcutaneous nodules on her abdomen and extremities, some with focal erosions (Fig. 2) . She experienced multiple episodes of fever accompanied by an elevated erythrocyte sedimentation rate, a Coombs-positive hemolytic anemia, IgA nephropathy, and chronic bilateral parotitis. The ANA was negative. The anti-smooth muscle antibodies were positive at a titer of 1:40. An initial DIF from lesional skin was positive showing a granular deposition of IgG and C3 at the dermal-epidermal junction. Three subsequent biopsies for DIF over a period of 5 years were negative. Her disease was initially controlled with high-dose oral corticosteroids but relapsed when the corticosteroids were tapered. She was then treated successfully with vorinostat. She has been in remission for 13 months (30 months after initial diagnosis of SPTCL) and is currently maintained on low-dose prednisone.
Histopathology/Immunopathology/Molecular Biology/In Situ Hybridization for EBV
The microscopical sections from all 5 patients revealed infiltrates of lymphocytes and histiocytes within subcutaneous lobules (Fig. 3A) . A variable degree of rimming of adipocytes by lymphocytes with pleomorphic nuclei and scant cytoplasm was a constant feature ( Fig. 3B) , as was focal fat necrosis ( Fig.  3C) . Lymphocytes with pleomorphic nuclei were observed in all cases (Fig. 3D ). Signs of interface dermatitis were present in all biopsies in which the epidermis was included in the histopathological section (cases 3-5) (Fig. 3E ). Dermal deposition of mucin was present in 2 of 3 biopsies in which the dermis was available for evaluation (cases 4 and 5). In 1 patient (case 4), there were germinal centers in the subcutaneous fat.
Immunohistology showed that the majority of the infiltrating lymphocytes were CD3 + /CD8 + /bF1 + and CD4 2 / CD30 2 /CD56 2 (Fig. 4A ). Cytotoxic markers, either TIA-1 (cases 1, 3, 4, and 5) or granzyme B (case 2), were positive in all cases (Fig. 4B) . Staining with MIB-1/Ki-67 showed a proliferation rate of over 50% in 4 cases (cases 1, 2, 4, and 5) ( Fig. 4C) , whereas in 1 case, the proliferation rate was about 30%-40% (case 3). In 1 patient, considerable numbers of B cells, partly arranged within germinal centers, were evident (case 4). Small numbers of B cells were also present in the other 4 cases. Staining with CD123 identified small clusters of pDCs within the adipose tissue of 1 patient (case 2).
Polymerase chain reaction analysis revealed a monoclonal TCR-g gene rearrangement population in 3 patients (cases 3-5) and a polyclonal smear in the other 2. EBV in situ hybridization was negative in all cases.
DISCUSSION
The 5 patients described herein exhibited typical histopathology of SPTCL, and a spectrum of manifestations like those seen in LE, including cutaneous lesions characteristic of LEP, serologic and/or extracutaneous end-organ manifestations, and histopathological findings of LE in sections from skin biopsies.
Histopathological attributes consistent with SPTCL included, in all cases, the presence of lymphocytes with pleomorphic nuclei and a cytotoxic CD3 + /CD8 + /bF1 + T-cell immunophenotype in fatty lobules. These cells exhibited a high proliferation rate and a monoclonal TCR-g gene rearrangement in 3 of 5 cases.
Clinical lesions that are prototypical of LEP, namely, subcutaneous nodules on the face that heal with lipoatrophy, were seen in 3 of the patients (cases 1-3) . Although there is an overlap of the clinical presentation of LEP and SPTCL, as both can appear above the waist, the location of lesions on the face with resolution of the lesions leaving gullies is particularly suggestive of LEP.
Serologic abnormalities and/or end-organ dysfunction (in addition to the cutaneous changes of LEP, as above) associated with SLE were seen in all the patients. Two patients (cases 1 and 3) met 4 of 11 ACR criteria for a diagnosis of SLE with detection of ANAs, elevated titers of anti-dsDNA antibodies, renal abnormalities, and anemia ( Table 1) . The 3 other patients exhibited features indicative but not decisively diagnostic of SLE. Patient 2 had lymphadenopathy, anemia, and neutropenia, and for many years, his disease was controlled with antimalarial medication. Patient 4 had antibodies to dsDNA. Although the ANA in this patient was reported to be negative, we suspect that this represented a laboratory anomaly as antibodies to dsDNA by definition stain the nucleus. Patient 5 had features of SLE with a Coombs-positive hemolytic anemia, IgA nephropathy, chronic bilateral parotitis, and a positive DIF. However, the negative ANA in patients 3 and 5 argues against a clear-cut diagnosis of SLE.
Histopathological evidence of LE on skin biopsies varied in the patients. In 2 patients, there were histopathological features of LEP concomitant with SPTCL (cases 2 and 4). In particular, in patient 4, a sizable number of B cells, including germinal centers, were present in the subcutaneous fat jointly with an interface dermatitis and dermal deposition of mucin. In patient 2, where neither the epidermis nor the dermis was present in the specimen, there were small clusters of CD123 + pDCs, as can be seen in LEP. In 1 patient (case 5), the histopathological features of LE were seen only in the epidermis and dermis, with an interface reaction and dermal mucin deposition. This patient also had a biopsy from lesional skin positive for DIF. In another patient (case 3), only an interface dermatitis was evident. In 1 case, a positive DIF on normal and lesional skin was the only histopathological feature of LE (case 1). Other histopathological manifestations of LE, such as epidermal basement membrane thickening, hyperkeratosis, and follicular plugging, were not present. Based on our data and those published in the literature, we believe that patients with SPTCL who have clinical or histopathological evidence of LE may suffer from an overlap of both disease entities. Large studies are needed to determine whether there is a definitive association between these disease states. However, the cases discussed in this report and in prior studies 1 provide clues that such a relationship might exist. In particular, the fact that 3 patients presented with clinical features favoring LEP, namely, nodules on the face resolving with marked lipoatrophy, suggests that SPTCL arose secondarily on the background of long-standing LEP.
Magro et al 19, 20 have addressed patients with overlapping features of SPTCL and LEP. They suggested that these patients should be categorized into a distinct classification separate from both SPTCL and LEP and proposed a new disease entity coined ''atypical lymphocytic lobular panniculitis.'' 19 They argued that the patients do not fit into the LEP category as they generally lack clinical or serological stigmata of LE. Furthermore, histopathological sections from these patients showed neither hyalinization of the fat lobules (a feature we did not highlight in our study) nor dermal or subcutaneous mucin deposition. The features that excluded the patients from the SPTCL category were clinical response of the lesions to immunosuppression; the infiltrates were not sufficiently dense and/or atypical; and there was a lack of vascular thrombosis, fat necrosis, or erythrophagocytosis. 19 However, in the most recent description of SPTCL based on the WHO-EORTC consensus statement, some of the features used to exclude patients from the SPTCL category, such as response to immunosuppression and the absence of hemophagocytosis (including erythrophagocytosis), were actually found to be characteristic of SPTCL (hemophagocytosis is more commonly seen in the aggressive cutaneous gd T-cell lymphoma). 1 Therefore, we suspect that at least some of the patients categorized by Magro et al as atypical lymphocytic lobular panniculitis would better be classified as SPTCL based on the WHO-EORTC system. Our data instead suggest that patients described herein straddle SPTCL and LE rather than representing a new disease entity.
The increased risk of developing secondary malignancies in patients with autoimmune disease has been well documented, and it is well known that patients with SLE have an increased standardized incidence ratio of 3.64 (95% confidence interval 2.63-4.93) of developing non-Hodgkin lymphoma (NHL), usually B-cell NHL. 21, 22 Possible explanations as to why patients with SLE are at increased risk for developing NHL include immune derangement, induction by medication, viral infection, or genetic factors. 21 Most data suggest that use of immunosuppressive agents is not associated with the development of NHL in patients with LE, 23 although other studies have not been conclusive. 24 It may be that patients with SLE and signs of LEP are at higher risk of developing SPTCL as they have active inflammation and immune dysregulation in the subcutaneous tissue. Alternatively, as patients with NHL have an increased prevalence of both autoantibodies 25, 26 and clinical autoimmune phenomena, 25, 27 patients with SPTCL may be particularly susceptible to developing autoantibodies and possibly clinical autoimmune phenomena such as LE.
This report illustrates that patients with SPTCL may additionally exhibit clinical or histopathological features of LE, in particular LEP, or abnormalities seen in SLE. Of note, our data show that a positive DIF test cannot exclude a diagnosis of SPTCL, as 2 of the patients described herein had positive DIF results. We aim to make physicians aware of the possibility that these conditions can overlap in the same patient. We suggest that it is prudent to monitor patients with LE, particularly LEP, for evolution into SPTCL with biopsy of any suspicious subcutaneous lesion. Additionally, as other have suggested, it is prudent to screen patients with SPTCL for cutaneous LE and SLE. 1 
